No Data
No Data
Cassava Alzheimer's Drug Set for First Phase 3 Readout by December 2024
JonesTrading Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $15
JonesTrading analyst Soumit Roy maintains $Anavex Life Sciences(AVXL.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 23.2%
Express News | EF Hutton Initiates Coverage On Anavex Life Sciences With Buy Rating, Announces Price Target of $46
CrossFirst Bankshares Posts Q2 Earnings, Joins Owens & Minor, Reddit And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 40 points on Tuesday.Shares of CrossFirst Bankshares, Inc. (NASDAQ:CFB) fell sharply in today's pre-market trading
Why Match Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Match Group, Inc. (NASDAQ:MTCH) rose sharply in today's pre-market trading.Starboard Value has taken a keen interest in Match Group. The hedge fund has accumulated a stake of over 6.5% in
Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of
No Data